These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 32854564)
1. Eplerenone for treatment of chronic central serous chorioretinopathy. Fraenkel D; Suffo S; Langenbucher A; Seitz B; Abdin AD Eur J Ophthalmol; 2021 Jul; 31(4):1885-1891. PubMed ID: 32854564 [TBL] [Abstract][Full Text] [Related]
2. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785 [TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F Retina; 2013; 33(10):2096-102. PubMed ID: 23719402 [TBL] [Abstract][Full Text] [Related]
5. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R Am J Ophthalmol; 2019 Feb; 198():80-87. PubMed ID: 30308202 [TBL] [Abstract][Full Text] [Related]
6. Predictors of Outcome During Eplerenone Therapy in Chronic Central Serous Chorioretinopathy:A Prospective, Open-Label Pilot Clinical Study. Rajesh B; Agrawal H; Peguda HK; Chhablani J Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):479-486. PubMed ID: 30021034 [TBL] [Abstract][Full Text] [Related]
7. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Sun X; Shuai Y; Fang W; Li J; Ge W; Yuan S; Liu Q Br J Ophthalmol; 2018 Aug; 102(8):1060-1065. PubMed ID: 29089356 [TBL] [Abstract][Full Text] [Related]
8. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864 [TBL] [Abstract][Full Text] [Related]
9. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial. Willcox A; Culliford L; Ellis L; Rogers CA; Cree A; Chakravarthy U; Ennis S; Behar-Cohen F; Reeves BC; Sivaprasad S; Lotery A Eye (Lond); 2019 Feb; 33(2):295-303. PubMed ID: 30194380 [TBL] [Abstract][Full Text] [Related]
11. Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients. Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Schlingemann RO; Hoyng CB; Boon CJF Ophthalmol Retina; 2022 Oct; 6(10):930-938. PubMed ID: 35470085 [TBL] [Abstract][Full Text] [Related]
12. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy. Zola M; Daruich A; Matet A; Mantel I; Behar-Cohen F Br J Ophthalmol; 2019 Aug; 103(8):1184-1189. PubMed ID: 30355720 [TBL] [Abstract][Full Text] [Related]
13. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy. Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972 [TBL] [Abstract][Full Text] [Related]
14. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. Petkovsek DS; Cherfan DG; Conti FF; Hom GL; Ehlers JP; Babiuch AS; Rachitskaya AV; Kaiser PK; Schachat AP; Srivastava SK; Sharma S; Singh RP Br J Ophthalmol; 2020 Feb; 104(2):182-187. PubMed ID: 31079056 [TBL] [Abstract][Full Text] [Related]
15. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P; Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733 [TBL] [Abstract][Full Text] [Related]
16. Subthreshold laser compared to oral spironolactone for the treatment of chronic central serous chorioretinopathy: a retrospective study. Mercuri S; D'Alterio FM; Gallo B; Raslan W; Gupta A; Khairat N; Corazza P; Younis S Int Ophthalmol; 2024 Mar; 44(1):131. PubMed ID: 38478131 [TBL] [Abstract][Full Text] [Related]
17. [Eplerenone treatment in chronic central serous chorioretinopathy]. Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892 [TBL] [Abstract][Full Text] [Related]
18. Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy. Yavuz S; Balsak S; Karahan M; Dursun B J Fr Ophtalmol; 2021 Jan; 44(1):13-23. PubMed ID: 33279285 [TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3. Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Hoyng CB; Schlingemann RO; Boon CJF Graefes Arch Clin Exp Ophthalmol; 2023 Mar; 261(3):659-668. PubMed ID: 36202933 [TBL] [Abstract][Full Text] [Related]
20. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES. Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]